Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia

被引:77
作者
Aygun, Banu [1 ]
Mortier, Nicole A. [4 ]
Smeltzer, Matthew P. [2 ]
Shulkin, Barry L. [3 ]
Hankins, Jane S. [1 ]
Ware, Russell E. [4 ]
机构
[1] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA
[3] St Jude Childrens Res Hosp, Dept Radiol Sci, Memphis, TN 38105 USA
[4] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
关键词
YOUNG-CHILDREN; RENAL-FUNCTION; TRIAL; MICROALBUMINURIA; MULTICENTER; PREVALENCE; DISEASE;
D O I
10.1002/ajh.23365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glomerular hyperfiltration and microalbuminuria/proteinuria are early manifestations of sickle nephropathy. The effects of hydroxyurea therapy on these renal manifestations of sickle cell anemia (SCA) are not well defined. Our objective was to investigate the effects of hydroxyurea on glomerular filtration rate (GFR) measured by 99mTc-DTPA clearance, and on microalbuminuria/proteinuria in children with SCA. Hydroxyurea study of long-term effects (HUSTLE) is a prospective study (NCT00305175) with the goal of describing the long-term cellular, molecular, and clinical effects of hydroxyurea therapy in SCA. Glomerular filtration rate, urine microalbumin, and serum cystatin C were measured before initiating hydroxyurea therapy and then repeated after 3 years. Baseline and Year 3 values for HUSTLE subjects were compared using the Wilcoxon Signed Rank test. Associations between continuous variables were evaluated using Spearman correlation coefficient. Twenty-three children with SCA (median age 7.5 years, range, 2.5-14.0 years) received hydroxyurea at maximum tolerated dose (MTD, 24.4 +/- 4.5 mg/kg/day, range, 15.3-30.6 mg/kg/day). After 3 years of treatment, GFR measured by 99mTc-DTPA decreased significantly from 167 +/- 46 mL/min/1.73 m2 to 145 +/- 27 mL/min/1.73 m2 (P = 0.016). This decrease in GFR was significantly associated with increase in fetal hemoglobin (P = 0.042) and decrease in lactate dehydrogenase levels (P = 0.035). Urine microalbumin and cystatin C levels did not change significantly. Hydroxyurea at MTD is associated with a decrease in hyperfiltration in young children with SCA. Am. J. Hematol., 88:116-119, 2013. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:116 / 119
页数:4
相关论文
共 26 条
[1]   EFFECTS OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON RENAL-FUNCTION IN SICKLE-CELL ANEMIA [J].
ALLON, M ;
LAWSON, L ;
ECKMAN, JR ;
DELANEY, V ;
BOURKE, E .
KIDNEY INTERNATIONAL, 1988, 34 (04) :500-506
[2]   Early blood transfusions protect against microalbuminuria in children with sickle cell disease [J].
Alvarez, Ofelia ;
Montane, Brenda ;
Lopez, Gabriela ;
Wilkinson, James ;
Miller, Tracie .
PEDIATRIC BLOOD & CANCER, 2006, 47 (01) :71-76
[3]   Effect of hydroxyurea treatment on renal function parameters: Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia [J].
Alvarez, Ofelia ;
Miller, Scott T. ;
Wang, Winfred C. ;
Luo, Zhaoyu ;
McCarville, M. Beth ;
Schwartz, George J. ;
Thompson, Bruce ;
Howard, Thomas ;
Iyer, Rathi V. ;
Rana, Sohail R. ;
Rogers, Zora R. ;
Sarnaik, Sharada A. ;
Thornburg, Courtney D. ;
Ware, Russell E. .
PEDIATRIC BLOOD & CANCER, 2012, 59 (04) :668-674
[4]  
Ataga KI, 2000, AM J HEMATOL, V63, P205, DOI 10.1002/(SICI)1096-8652(200004)63:4<205::AID-AJH8>3.3.CO
[5]  
2-#
[6]   Glomerular hyperfiltration and albuminuria in children with sickle cell anemia [J].
Aygun, Banu ;
Mortier, Nicole A. ;
Smeltzer, Matthew P. ;
Hankins, Jane S. ;
Ware, Russell E. .
PEDIATRIC NEPHROLOGY, 2011, 26 (08) :1285-1290
[7]   Renal nitric oxide synthases in transgenic sickle cell mice [J].
Bank, N ;
Aynedjian, HS ;
Qiu, JH ;
Osei, SY ;
Ahima, RS ;
Fabry, ME ;
Nagel, RL .
KIDNEY INTERNATIONAL, 1996, 50 (01) :184-189
[8]  
CHARACHE S, 1992, BLOOD, V79, P2555
[9]   EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA [J].
CHARACHE, S ;
TERRIN, ML ;
MOORE, RD ;
DOVER, GJ ;
BARTON, FB ;
ECKERT, SV ;
MCMAHON, RP ;
BONDS, DR ;
ORRINGER, E ;
JONES, S ;
STRAYHORN, D ;
ROSSE, W ;
PHILLIPS, G ;
PEACE, D ;
JOHNSONTELFAIR, A ;
MILNER, P ;
KUTLAR, A ;
TRACY, A ;
BALLAS, SK ;
ALLEN, GE ;
MOSHANG, J ;
SCOTT, B ;
STEINBERG, M ;
ANDERSON, A ;
SABAHI, V ;
PEGELOW, C ;
TEMPLE, D ;
CASE, E ;
HARRELL, R ;
CHILDERIE, S ;
EMBURY, S ;
SCHMIDT, B ;
DAVIES, D ;
KOSHY, M ;
TALISCHYZAHED, N ;
DORN, L ;
PENDARVIS, G ;
MCGEE, M ;
TELFER, M ;
DAVIS, A ;
CASTRO, O ;
FINKE, H ;
PERLIN, E ;
SITEMAN, J ;
GASCON, P ;
DIPAOLO, P ;
GARGIULO, S ;
ECKMAN, J ;
BAILEY, JH ;
PLATT, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1317-1322
[10]   Enalapril and hydroxyurea therapy for children with sickle nephropathy [J].
Fitzhugh, CD ;
Wigfall, DR ;
Ware, RE .
PEDIATRIC BLOOD & CANCER, 2005, 45 (07) :982-985